Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
NCT06541327 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2024-08-19
Summary
This study aims to collect clinical data from adult patients with relapsed or refractory non-Hodgkin's lymphoma (r/r NHL) receiving cellular immunotherapy to establish a large database of cellular immunotherapy for Chinese patients.
Conditions
- Lymphoma, Non-Hodgkin
Interventions
- DRUG
-
Chimeric Antigen Receptor
CAR-T
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-05-15
- Primary Completion
- 2040-12-31
- Completion
- 2040-12-31
Countries
- China
Study Locations
More Related Trials
-
A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT04129710 ·Status: RECRUITING ·Phase: PHASE2
-
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
NCT05821192 ·Status: UNKNOWN ·Phase: NA
-
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
NCT05615974 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients
NCT01788137 ·Status: UNKNOWN ·Phase: PHASE3
-
Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma
NCT01965119 ·Status: COMPLETED ·Phase: PHASE2
-
Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05318391 ·Status: COMPLETED
-
Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
NCT06695013 ·Status: RECRUITING ·Phase: PHASE2
-
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
NCT05618925 ·Status: RECRUITING ·Phase: PHASE1
-
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
NCT05179213 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT05091541 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05623982 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Glofitamab in Chinese Patients With R/R DLBCL
NCT06481826 ·Status: RECRUITING
-
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT06693973 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
NCT05186558 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
NCT03155425 ·Status: COMPLETED ·Phase: PHASE2
-
China Lymphoma Patient Registry Study
NCT03313271 ·Status: RECRUITING
-
Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years
NCT05429918 ·Status: UNKNOWN
-
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
NCT06656234 ·Status: NOT_YET_RECRUITING
-
Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors
NCT02929615 ·Status: UNKNOWN ·Phase: PHASE4
-
A Phase I/II Study of Diffuse Large B-cell Lymphoma
NCT04856137 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05182957 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
NCT05267054 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
NCT04923789 ·Status: UNKNOWN
-
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT01880567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2